HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies
Bobrowicz M, Dwojak M, Bojarczuk K et al.
Key Points:
Study aim: understand how inhibition of HDAC6 activity influences CD20 level in normal and malignant B-cells.
Results: both pan-HDAC and HDAC6 inhibition lead to increase expression of CD20 antigen on surface of B-lymphocytes.
HDAC inhibition also increased potency of anti-CD20 monoclonal antibodies (Rituximab and Ofatumumab) for cytotoxicity.
Experiments also revealed that increase in CD20 antigen expression not due to increase transcription; rather post-transcriptional event and possibly due to intracellular trafficking.
Implications:
- Combining HDACi with anti-CD20 antibodies can be effective therapeutic strategy for patients with B-cell malignancies.
View the original abstract on the ASH website.
